Solbec soars 70 per cent on cancer drug result
Tuesday, 23 November, 2004
Shares in Solbec Pharmaceuticals (ASX:SBP) jumped almost 70 per cent to $0.21 today after preliminary results from a study conducted by the Tumour Immunology Group at the University of Western Australia indicated that the company's cancer drug, Coramsine, was effective in treating and preventing mesothelioma in a mouse model of the cancer.
Mice treated with Coramsine in combination with the immune-triggering compound CpG -- a synthetic DNA fragment containing cytosine and guanine -- showed total remission of the mesothelioma. The therapy also seemed to confer lasting immunity against mesothelioma, as attempts to cause tumour formation in a treated, 'cured' mouse failed.
Coramsine is a mixture of two alkaloids from the prickly weed Solanum linneaum, also known as devil's apple.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
